The life and times of ivermectin - a success story.
Identifieur interne : 003E52 ( PubMed/Curation ); précédent : 003E51; suivant : 003E53The life and times of ivermectin - a success story.
Auteurs : Satoshi Omura [Japon] ; Andy CrumpSource :
- Nature reviews. Microbiology [ 1740-1526 ] ; 2004.
Descripteurs français
- KwdFr :
- Afrique (épidémiologie), Amériques (épidémiologie), Animaux, Antihelminthiques (), Antihelminthiques (métabolisme), Antihelminthiques (usage thérapeutique), Antihelminthiques (économie), Coûts et analyse des coûts, Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (), Ivermectine (métabolisme), Ivermectine (usage thérapeutique), Ivermectine (économie), Onchocerca volvulus (physiologie), Onchocercose (médecine vétérinaire), Onchocercose (traitement médicamenteux), Onchocercose (épidémiologie), Réseaux communautaires, Streptomyces (métabolisme), Étapes du cycle de vie.
- MESH :
- médecine vétérinaire : Onchocercose.
- métabolisme : Antihelminthiques, Ivermectine, Streptomyces.
- physiologie : Onchocerca volvulus.
- traitement médicamenteux : Filariose lymphatique, Onchocercose.
- usage thérapeutique : Antihelminthiques, Ivermectine.
- économie : Antihelminthiques, Ivermectine.
- épidémiologie : Afrique, Amériques, Onchocercose.
- Animaux, Antihelminthiques, Coûts et analyse des coûts, Humains, Ivermectine, Réseaux communautaires, Étapes du cycle de vie.
English descriptors
- KwdEn :
- Africa (epidemiology), Americas (epidemiology), Animals, Anthelmintics (chemistry), Anthelmintics (economics), Anthelmintics (metabolism), Anthelmintics (therapeutic use), Community Networks, Costs and Cost Analysis, Elephantiasis, Filarial (drug therapy), Humans, Ivermectin (chemistry), Ivermectin (economics), Ivermectin (metabolism), Ivermectin (therapeutic use), Life Cycle Stages, Onchocerca volvulus (physiology), Onchocerciasis (drug therapy), Onchocerciasis (epidemiology), Onchocerciasis (veterinary), Streptomyces (metabolism).
- MESH :
- chemical , chemistry : Anthelmintics, Ivermectin.
- chemical , economics : Anthelmintics, Ivermectin.
- geographic , epidemiology : Africa, Americas.
- chemical , metabolism : Anthelmintics, Ivermectin.
- chemical , therapeutic use : Anthelmintics, Ivermectin.
- drug therapy : Elephantiasis, Filarial, Onchocerciasis.
- epidemiology : Onchocerciasis.
- metabolism : Streptomyces.
- physiology : Onchocerca volvulus.
- veterinary : Onchocerciasis.
- Animals, Community Networks, Costs and Cost Analysis, Humans, Life Cycle Stages.
Abstract
Since its introduction more than 20 years ago, ivermectin has proved to be one of the most successful therapeutic drugs in veterinary medicine, as well as the basis of one of the most successful public-health programmes of the past century. The drug arose from a unique international collaboration between the public and private sectors. The development process also incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry. The drug is now being used, free of charge, in two global disease-elimination programmes that are benefiting millions of the world's poorest people.
DOI: 10.1038/nrmicro1048
PubMed: 15550944
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003E52
Links to Exploration step
pubmed:15550944Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The life and times of ivermectin - a success story.</title><author><name sortKey="Omura, Satoshi" sort="Omura, Satoshi" uniqKey="Omura S" first="Satoshi" last="Omura">Satoshi Omura</name><affiliation wicri:level="1"><nlm:affiliation>Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642, Japan. omura-s@kitasato.or.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642</wicri:regionArea></affiliation></author><author><name sortKey="Crump, Andy" sort="Crump, Andy" uniqKey="Crump A" first="Andy" last="Crump">Andy Crump</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15550944</idno><idno type="pmid">15550944</idno><idno type="doi">10.1038/nrmicro1048</idno><idno type="wicri:Area/PubMed/Corpus">003E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003E52</idno><idno type="wicri:Area/PubMed/Curation">003E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003E52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The life and times of ivermectin - a success story.</title><author><name sortKey="Omura, Satoshi" sort="Omura, Satoshi" uniqKey="Omura S" first="Satoshi" last="Omura">Satoshi Omura</name><affiliation wicri:level="1"><nlm:affiliation>Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642, Japan. omura-s@kitasato.or.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642</wicri:regionArea></affiliation></author><author><name sortKey="Crump, Andy" sort="Crump, Andy" uniqKey="Crump A" first="Andy" last="Crump">Andy Crump</name></author></analytic><series><title level="j">Nature reviews. Microbiology</title><idno type="ISSN">1740-1526</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa (epidemiology)</term><term>Americas (epidemiology)</term><term>Animals</term><term>Anthelmintics (chemistry)</term><term>Anthelmintics (economics)</term><term>Anthelmintics (metabolism)</term><term>Anthelmintics (therapeutic use)</term><term>Community Networks</term><term>Costs and Cost Analysis</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Humans</term><term>Ivermectin (chemistry)</term><term>Ivermectin (economics)</term><term>Ivermectin (metabolism)</term><term>Ivermectin (therapeutic use)</term><term>Life Cycle Stages</term><term>Onchocerca volvulus (physiology)</term><term>Onchocerciasis (drug therapy)</term><term>Onchocerciasis (epidemiology)</term><term>Onchocerciasis (veterinary)</term><term>Streptomyces (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique (épidémiologie)</term><term>Amériques (épidémiologie)</term><term>Animaux</term><term>Antihelminthiques ()</term><term>Antihelminthiques (métabolisme)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Antihelminthiques (économie)</term><term>Coûts et analyse des coûts</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine ()</term><term>Ivermectine (métabolisme)</term><term>Ivermectine (usage thérapeutique)</term><term>Ivermectine (économie)</term><term>Onchocerca volvulus (physiologie)</term><term>Onchocercose (médecine vétérinaire)</term><term>Onchocercose (traitement médicamenteux)</term><term>Onchocercose (épidémiologie)</term><term>Réseaux communautaires</term><term>Streptomyces (métabolisme)</term><term>Étapes du cycle de vie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Africa</term><term>Americas</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Streptomyces</term></keywords><keywords scheme="MESH" qualifier="médecine vétérinaire" xml:lang="fr"><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antihelminthiques</term><term>Ivermectine</term><term>Streptomyces</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Onchocerca volvulus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Onchocerca volvulus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antihelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Afrique</term><term>Amériques</term><term>Onchocercose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Community Networks</term><term>Costs and Cost Analysis</term><term>Humans</term><term>Life Cycle Stages</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Antihelminthiques</term><term>Coûts et analyse des coûts</term><term>Humains</term><term>Ivermectine</term><term>Réseaux communautaires</term><term>Étapes du cycle de vie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since its introduction more than 20 years ago, ivermectin has proved to be one of the most successful therapeutic drugs in veterinary medicine, as well as the basis of one of the most successful public-health programmes of the past century. The drug arose from a unique international collaboration between the public and private sectors. The development process also incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry. The drug is now being used, free of charge, in two global disease-elimination programmes that are benefiting millions of the world's poorest people.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15550944</PMID><DateCreated><Year>2004</Year><Month>11</Month><Day>19</Day></DateCreated><DateCompleted><Year>2004</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1740-1526</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>12</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature reviews. Microbiology</Title><ISOAbbreviation>Nat. Rev. Microbiol.</ISOAbbreviation></Journal><ArticleTitle>The life and times of ivermectin - a success story.</ArticleTitle><Pagination><MedlinePgn>984-9</MedlinePgn></Pagination><Abstract><AbstractText>Since its introduction more than 20 years ago, ivermectin has proved to be one of the most successful therapeutic drugs in veterinary medicine, as well as the basis of one of the most successful public-health programmes of the past century. The drug arose from a unique international collaboration between the public and private sectors. The development process also incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry. The drug is now being used, free of charge, in two global disease-elimination programmes that are benefiting millions of the world's poorest people.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Omura</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642, Japan. omura-s@kitasato.or.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crump</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Microbiol</MedlineTA><NlmUniqueID>101190261</NlmUniqueID><ISSNLinking>1740-1526</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000569" MajorTopicYN="N" Type="Geographic">Americas</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="Y">Anthelmintics</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019058" MajorTopicYN="N">Community Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="Y">Ivermectin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008018" MajorTopicYN="N">Life Cycle Stages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017181" MajorTopicYN="N">Onchocerca volvulus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009855" MajorTopicYN="N">Onchocerciasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013302" MajorTopicYN="N">Streptomyces</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>53</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15550944</ArticleId><ArticleId IdType="pii">nrmicro1048</ArticleId><ArticleId IdType="doi">10.1038/nrmicro1048</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003E52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15550944
|texte= The life and times of ivermectin - a success story.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15550944" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |